Giuseppe Viscardi - Publications

Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 14, 2026

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 20, 2025

Bone metastases in NSCLC: Modern paradigms in management and supportive care.

Journal: Cancer treatment reviews

Published: August 07, 2025

Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies.

Journal: International journal of molecular sciences

Published: July 14, 2025

Response to "Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients With Resectable NSCLC: Still an Open Question" by Dafni et al.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 27, 2025

Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis.

Journal: Critical reviews in oncology/hematology

Published: June 25, 2025

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.

Journal: The Cochrane database of systematic reviews

Published: May 27, 2025

Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 10, 2025

Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.

Journal: EClinicalMedicine

Published: April 24, 2025

APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer.

Journal: NPJ precision oncology

Published: April 03, 2025

Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 20, 2025